Company Overview
Company Type: Public Company
Website: www.oncolyticsbiotech.com
Number of Employees: 29
Ticker: ONC (TSX)
Year Founded: 1998


Business Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
206.9
EBITDA
(28.4)
Total Enterprise Value
183.0
TEV/EBITDA
NM
EBIT
(28.5)
Cash & ST Invst.
24.4
P/Diluted EPS Before Extra
NM
Net Income
(26.8)
Total Debt
0.5
Price/Tang BV
8.3x
Capital Expenditure
0.0
Total Assets
32.0
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.11)
(0.11)
(0.43)
(0.43)
(0.42)
Revenue (mm)
0.00
0.00
0.00
1.00
0.00
EBITDA (mm)
(7.35)
(7.57)
(28.77)
(37.16)
(32.97)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Outperform (1.67)
Target Price
7.83
Potential Upside
177.78%


Key Professionals
Name
Title
Coffey, Matthew C.
President, CEO & Director
Look, Kirk J.
Chief Financial Officer
Patton, Jon 
Director of Investor Relations & Communication
de Guttadauro, Andrew R.
Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc
Heineman, Thomas C.
Chief Medical Officer
Hagerman, Allison 
Vice President of Product Development
Lievonen, John Mark
Consultant

Key Board Members
Name
Title
Pisano, Wayne F.
Independent Chairman of the Board
Coffey, Matthew C.
President, CEO & Director
Brown, Deborah M.
Independent Director
Holtham, Angela Frances
Independent Director
Bizzari, Jean-Pierre 
Member of Scientific Advisory Board
Parsons, James T.
Independent Director
Piccart, Martine 
Member of Scientific Advisory Board
Prat, Aleix 
Member of Scientific Advisory Board
Rigby, Jonathan M. N.
Director
Seizinger, Bernd Robert
Independent Director
Sharma, Padmanee 
Member of Scientific Advisory Board
Vile, Richard 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
322 11th Avenue SW Suite 804 | Calgary, AB | T2R 0C5 | Canada
Phone: 403 670 7377   

Current and Pending Investors
Tourmaline Oil Corp. (TSX:TOU)

Prior Investors
Chinook Energy Inc., Innovatech Grand Montreal, Iteration Energy Ltd., Multiple Capital Inc., Prior to Change in line of business

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 2.81
Market Cap (mm)
206.9
Open
 2.82
Shares Out. (mm)
73.4
Previous Close
 2.82
Float %
98.8%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(0.4)%
Dividend Yield %
-
Day High/Low
 2.87/ 2.73
Diluted EPS Excl. Extra Items
(0.44)
52 wk High/Low
 4.49/ 1.48
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.17
Beta 5Y
1.67


 
Delayed Quote** | Last Updated on Oct-05-2023 03:04 PM (GMT-5)
TSX:ONC - Common Stock


Index Membership
S&P/TSX SmallCap Index;S&P/TSX Smallcap Index - Biotechnology (Industry);S&P/TSX Smallcap Index - Biotechnology (Sub Industry);S&P/TSX Smallcap Index - Health Care (Sector);S&P/TSX Smallcap Index - Pharmaceuticals & Biotechnology (Industry Group)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
ONCOLYTICS BIOTECH (BARBADOS) INC

Latin America and Caribbean
-
-
-
-
Oncolytics Biotech (U.S.) Inc.
Oncolytics Biotech (U.S.) Inc. is a research and consulting services company. It is based in New York, New York.

United States and Canada
Research and Consulting Services
2.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-31-2023
Aug-8-2023
Public Offering
Target
Oncolytics Biotech Inc. (TSX:ONC)


15.00
Jun-17-2022
-
Public Offering
Target
Oncolytics Biotech Inc. (TSX:ONC)


65.00
Jun-17-2022
-
Shelf Registration
Target
Oncolytics Biotech Inc. (TSX:ONC)


0.06
Jun-9-2022
-
Shelf Registration
Target
Oncolytics Biotech Inc. (TSX:ONC)


118.62
Mar-5-2021
-
Public Offering
Target
Oncolytics Biotech Inc. (TSX:ONC)


80.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Company Conference Presentations
Oncolytics Biotech Inc. Presents at Cantor Fitzgerald Annual Global Healthcare Conference 2023, Sep-27-2023 08:35 AM
Sep-20-2023
Product-Related Announcements
Oncolytics Biotech Inc. Unveils Results from Its Phase 2 Trial of A Drug for Metastatic Breast Cancer
Sep-12-2023
Company Conference Presentations
Oncolytics Biotech Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-12-2023 09:30 AM
Aug-14-2023
Earnings Calls
Oncolytics Biotech Inc., Q2 2023 Earnings Call, Aug 14, 2023
Aug-10-2023
Company Conference Presentations
Oncolytics Biotech Inc. Presents at Canaccord Genuity 43rd Annual Growth Conference, Aug-10-2023 12:00 PM

M&A Advisors
Ernst & Young LLP


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Ernst & Young LLP
Private Placement Advisors
Osprey Capital Partners Inc.
Public Offering Advisors
Bennett Jones LLP, Dorsey & Whitney LLP, Ernst & Young LLP, Ernst & Young LLP (Canada), McCarthy Tétrault LLP, Norton Rose Fulbright Canada LLP


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:24 AM
ONC
Oncolytics Biotech Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:29 AM
ONC
ValuEngine - Toronto Quantitative Stock Report for ONC
Reports
9
ValuEngine, Inc.

Oct 02, 2023 05:08 AM
ONC
ValuEngine Rating and Forecast Report for ONCY
Reports
11
CFRA Equity Research

Oct 01, 2023 10:17 AM
ONC
Oncolytics Biotech Inc.
Reports
9
GlobalData

Sep 21, 2023 05:46 AM
ONC
Oncolytics Biotech Inc (ONCY.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
55
GlobalData

Sep 20, 2023 05:04 AM
ONC
Oncolytics Biotech Inc (ONC.TSE) - Financial and Strategic SWOT Analysis Review
Reports
236
Jefferson Research & Management

Sep 15, 2023 12:58 PM
ONC
Jefferson Financial - Oncolytics Biotech Inc.
Reports
11
GlobalData

Sep 12, 2023 06:42 AM
ONC
Oncolytics Biotech Inc (ONCY.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
31
Jefferson Research & Management

Sep 08, 2023 01:01 PM
ONC
Jefferson Financial - Oncolytics Biotech Inc.
Reports
11
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 08, 2023 06:40 AM
ONC
Rating Update for Oncolytics Biotech Inc
EPS Estimates*
3


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Seizinger M.D., Ph.D., Bernd Robert

314,863

0.43

0.9

Aug-15-2023


International Assets Investment Management, LLC

194,963

0.27

0.5

Jun-30-2023


Pisano M.B.A., MBA, Wayne F.

189,941

0.26

0.5

Aug-15-2023


Morgan Stanley, Investment Banking and Brokerage Investments

184,213

0.25

0.5

Jun-30-2023


Holtham F.C.M.A., FCMA, FCPA, ICD.D, M.B.A., Angela Frances

127,238

0.17

0.4

Aug-15-2023


Coffey M.B.A., Ph.D., Matthew C.

96,333

0.13

0.3

Aug-15-2023


PSM Vermogensverwaltung GmbH

70,000

0.10

0.2

Jun-30-2023


BNP Paribas Arbitrage Sa, Asset Management Arm

68,320

0.09

0.2

Jun-30-2023


Canadian Imperial Bank of Commerce, Asset Management Arm

60,913

0.08

0.2

Jun-30-2023


RBC Dominion Securities Inc., Asset Management Arm

53,205

0.07

0.1

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Morgan Stanley, Investment Banking and Brokerage Investments
184,213
77,228
PSM Vermogensverwaltung GmbH
70,000
70,000
BNP Paribas Arbitrage Sa, Asset Management Arm
68,320
68,320
HeadInvest, LLC
11,534
11,534
Brave Asset Management, Inc.
10,000
10,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
FSC Securities Corporation, Asset Management Arm
1,229
(226,196)
Renaissance Technologies LLC
0
(129,856)
Citadel Advisors LLC
0
(87,858)
Virtu Financial LLC, Asset Management Arm
0
(22,918)
Tower Research Capital LLC
2,639
(13,378)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Licensing of Pelareorep, Paclitaxel + Pelareorep + Avelumab (Future), Pelareorep (Future), Pelareorep + Paclitaxel (Future), Tecentriq (Future)


Upcoming Events
Date/Time
Type
Nov-06-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-26-2023
Sep-26-2023
Oncolytics Biotech Inc. (TSX:ONC)
SEC
6-K
39 KB
Sep-26-2023
-
Oncolytics Biotech Inc. (TSX:ONC)
SEDAR
News Releases
59 KB
Sep-26-2023
-
Oncolytics Biotech Inc. (TSX:ONC)
SEDAR
News Releases
59 KB
Sep-26-2023
-
Oncolytics Biotech Inc. (TSX:ONC)
SEDAR
News Releases
59 KB
Sep-19-2023
Sep-19-2023
Oncolytics Biotech Inc. (TSX:ONC)
SEC
6-K
28 KB
Sep-19-2023
-
Oncolytics Biotech Inc. (TSX:ONC)
SEDAR
News Releases
41 KB
Sep-07-2023
-
Oncolytics Biotech Inc. (TSX:ONC)
SEDAR
News Releases
55 KB
Sep-06-2023
Sep-06-2023
Oncolytics Biotech Inc. (TSX:ONC)
SEC
6-K
29 KB
Sep-06-2023
-
Oncolytics Biotech Inc. (TSX:ONC)
SEDAR
News Releases
32 KB
Aug-25-2023
-
Oncolytics Biotech Inc. (TSX:ONC)
SEDAR
Documents Affecting the Rights of Security Holders
406 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Hagerman P.Eng., P.M.P., Allison  (Vice President of Product Development)
Jun-16-2022
Common Shares
4,200
5,153
Open Market Acquisition
New
Multiple
Coffey M.B.A., Ph.D., Matthew C. (President, CEO & Director)
Jun-15-2022
Common Shares
7,900
9,162
Open Market Acquisition
8.93
Multiple
Look C.A., CA, Kirk J. (Chief Financial Officer)
Jun-15-2022
Common Shares
6,000
7,336
Open Market Acquisition
15.37
Multiple
Seizinger M.D., Ph.D., Bernd Robert (Independent Director)
Jun-14-2022
Common Shares
50,000
59,161
Open Market Acquisition
18.88
Multiple
Coffey M.B.A., Ph.D., Matthew C. (President, CEO & Director)
Jun-14-2022
Common Shares
5,774
6,623
Open Market Acquisition
6.99
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Pisano, Wayne F.
Independent Chairman of the Board
403 670 7377
-

Coffey, Matthew C.
President, CEO & Director
403 670 7377
-

Brown, Deborah M.
Independent Director
403 670 7377
-

Holtham, Angela Frances
Independent Director
403 670 7377
-

Bizzari, Jean-Pierre 
Member of Scientific Advisory Board
403 670 7377
-

Parsons, James T.
Independent Director
416-595-0627 x232
-

Piccart, Martine 
Member of Scientific Advisory Board
403 670 7377
-

Prat, Aleix 
Member of Scientific Advisory Board
403 670 7377
-

Rigby, Jonathan M. N.
Director
403 670 7377
-

Seizinger, Bernd Robert
Independent Director
403 670 7377
-

Sharma, Padmanee 
Member of Scientific Advisory Board
403 670 7377
-

Vile, Richard 
Member of Scientific Advisory Board
403 670 7377
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Coffey, Matthew C.
President, CEO & Director
403 670 7377
-

Look, Kirk J.
Chief Financial Officer
403 670 7377
-

Patton, Jon 
Director of Investor Relations & Communication
+1-858-886-7813
-
jpatton@oncolytics.ca
de Guttadauro, Andrew R.
Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc
403 670 7377
-

Heineman, Thomas C.
Chief Medical Officer
403 670 7377
-

Hagerman, Allison 
Vice President of Product Development
403 670 7377
-

Lievonen, John Mark
Consultant
403 670 7377
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
